Invitrogen™ SARS/SARS-CoV-2 Spike Protein (RBD) Chimeric Recombinant Mouse Monoclonal Antibody (D005)

Description

This product is a chimeric monoclonal antibody combining the constant domains of the human IgG1 molecule with mouse variable regions. The variable region was obtained from a mouse immunized with purified, recombinant SARS-CoV Spike RBD Protein. The antibody was produced using recombinant antibody technology.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold symptoms to severe effects including death and respiratory distress. The CoV Spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Of note is the Spike protein receptor-binding domain (RBD, S-RBD) in SARS-CoV-2 Spike protein which binds strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibits significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD in comparison. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells.